Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Comparing Copy Number Variations and SNPs

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CLADES - Contrastive Learning Augmented DifferEntial Splicing with Orthologous Positive Pairs.

bioRxiv : the preprint server for biology·2026

Same author

Efficient algorithms for simulating sequences along a phylogenetic tree.

Bioinformatics (Oxford, England)·2025

Same author

Comparative metagenomics using pan-metagenomic graphs.

bioRxiv : the preprint server for biology·2025

Same author

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer.

Cancer research·2025

Same author

Distributional bias compromises leave-one-out cross-validation.

Science advances·2025

Same author

Identification of Sample Processing Errors in Microbiome Studies Using Host Genetic Profiles.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

MutaGeneSys: estimating individual disease susceptibility based on genome-wide SNP array data.

Julia Stoyanovich¹, Itsik Pe'er

¹Department of Computer Science, Columbia University, 1214 Amsterdam Avenue, New York, NY 10025, USA. jds1@cs.columbia.edu

Bioinformatics (Oxford, England)

|December 1, 2007

Summary

MutaGeneSys is a new system that estimates disease susceptibility using genome-wide genotype data. It integrates multiple data sources to provide disease hypotheses, even with incomplete SNP data.

More Related Videos

Infinium Assay for Large-scale SNP Genotyping Applications

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Related Experiment Videos

Last Updated: Jul 9, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Infinium Assay for Large-scale SNP Genotyping Applications

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Area of Science:

Genomics
Bioinformatics
Computational Biology

Background:

Estimating disease susceptibility is crucial for personalized medicine.
Existing methods may struggle with incomplete genotype data.

Purpose of the Study:

To present MutaGeneSys, a novel system for disease susceptibility estimation.
To integrate diverse genomic and disease databases for enhanced prediction.

Main Methods:

Utilizes genome-wide genotype data.
Integrates data from the International HapMap project, whole-genome marker correlation, and the Online Mendelian Inheritance in Man (OMIM) database.
Accepts SNP data as input to generate disease susceptibility hypotheses.

Main Results:

MutaGeneSys can deliver disease susceptibility hypotheses even with incomplete SNP data.
The system is scalable and flexible, providing population, technology, and confidence-specific predictions.
Predictions are delivered in interactive time.

Conclusions:

MutaGeneSys offers a robust and flexible approach to disease susceptibility estimation.
The system's integration of multiple data sources enhances the accuracy and utility of predictions.
MutaGeneSys is available as an online resource and integrated into the HapMap Genome Browser.